

Supplemental table 1. Demographic parameters of study subjects

Characteristics	Normal	Case*	sig.
N	498	599	
<i>anthropometric characteristics</i>			
sex (M/F)	215/283	330/269	<.0001
age (year)	60.76±9.77	66.25±12.28	<.0001
smoking (none/stop/active)	241/214/43	333/102/164	<.0001
drinking (none/stop/active)	298/31/168	313/73/212	0.0013
WHR	0.88±0.06	0.93±0.06	<.0001
weight (kg)	61.74±9.15	61.43±11.34	NS
waist circumference (cm)	83.61±8.38	85.56±9.86	0.0026
<i>TOAST classification</i>			
LAA	-	94	ND
CE	-	23	
SVO	-	360	
SOE	-	11	
SUE	-	18	
<i>medical history</i>			
hypertension (Yes,%)	60(12.07)	337(56.83)	<.0001
<i>blood parameter</i>			
GOP (U/ml)	27.56±19.97	26.91±20.59	NS
GPT (U/ml)	26.04±20.26	25.79±23.97	NS
total cholesterol (mg/dL)	202.23±40.04	185.32±44.06	<.0001
triglyceride (mg/dL)	139.88±69.80	150.17±97.59	NS
HDL-cholesterol (mg/dL)	52.28±12.69	45.55±13.68	<.0001
LDL-cholesterol (mg/dL)	121.19±36.70	113.69±38.48	0.0019
bloog sugar (mg/dL)	99.75±10.79	111.18±32.64	<.0001

All results except sex, TOAST categories, smoking, drinking and hypertension are expressed as mean ± SD for continuous variables. NS: not significant. ND: not done. WHR: waist hip ratio. TOAST: Trial of ORG 10172 in Acute Stroke Treatment. LAA: large-artery atherosclerosis. CE: cardioembolism. SVO: small-vessel occlusion. SOE: stroke of other etiology. SUE: stroke of undetermined etiology. GOP: glutamate oxaloacetate transaminase. GPT: glutamate pyruvate transaminase. * : cerebral infarction patients. sig. : P-value using a Student's t-test or Wilcoxon rank-sum test in continuous variables, chi-square test or Fisher's exact test in categorical variables. P-values with statistical significance were presented in bold.

Supplemental table 2. Primer sets for PCR amplification and sequencing in promoter and exon regions of *NPY* gene

region	PCR amplification primer			sequencing primer		
	location	direction	sequence	location	direction	sequencing
promoter + exon1	,-2071	forward	CACATGGACCTTTACCGGTT	-2071	forward	CACATGGACCTTTACCGGTT
	1349	reverse	GTGCCTGATACTGTCCTGC	-1749	forward	CCTCAGAATAAGTTCTTATTC
				-1239	forward	AGAATCACTTGTCTTTTAGCA
				-280	reverse	CCAAAGCCCAAGTATCTGCCCT
			+243	reverse	TAGCCGCCAAGAGGGCTGGT	
Exon 2	,-2071	forward	CACATGGACCTTTACCGGTT	+1349	reverse	GTGCCTGATACTGTCCTGC
	1349	reverse	GTGCCTGATACTGTCCTGC			
Exon 3	5223	forward	CATATCCCAAATAGGAGACTAT	+5223	forward	CATATCCCAAATAGGAGACTAT
	5482	reverse	CCCTAGTCTAGAAGCCTGGT			
Exon 4	7730	forward	CAGTTCCCGGTCATCTTCA	+7760	reverse	CTGAATCTGCTAGTTGAGGG
	,+7760	reverse	CTGAATCTGCTAGTTGAGGG			

Supplemental table 3. Primer sets for PCR amplification and genotyping of each SNPs

SNPs		PCR amplification primer	genotyping primer
G-1484A	forward	GAATCAAGCTATGAACCTGCTATC	aatagaagatgtttgcactttacc
	reverse	GTGTAGAGTGTGCCCTGTACAAA	
C-1471T	forward	GAATCAAGCTATGAACCTGCTATC	agt tgctcgggggtgcttac
	reverse	GTGTAGAGTGTGCCCTGTACAAA	
C-399T	forward	GAATCAAGCTATGAACCTGCTATC	tcctccaacaggactacca
	reverse	GTGTAGAGTGTGCCCTGTACAAA	
A1201G	forward	GAATCAAGCTATGAACCTGCTATC	ggacatggccagatactactc
	reverse	GTGTAGAGTGTGCCCTGTACAAA	
C5325T	forward	CATTACCCAAATAGGAGACTAT	tgaatcagtgtctctgggct
	reverse	CACCTTGAGCTCTGCAACAATG	